Source comparison
Thymosin Alpha-1: Dose Count Comparison by Vial Size
| Vial Size | Reconstitution Volume | Solution Concentration | Target Dose per Injection | Doses per Vial (Theoretical) | Usable Doses (Accounting for Dead Space) | Professional Assessment ||—|—|—|—|—|—|| 2mg | 1.0mL | 2mg/mL | 0.4mg | 5 | 4–5 | Best for short
This comparison does not assign a generated winner or score.
- | Vial Size | Reconstitution Volume | Solution Concentration | Target Dose per Injection | Doses per Vial (Theoretical) | Usable Doses (Accounting for Dead Space) | Professional Assessment ||—|—|—|—|—|—|| 2mg | 1.0mL | 2mg/mL | 0.4mg | 5 | 4–5 | Best for short pilot studies; limited dose flexibility || 5mg | 2.0mL | 2.5mg/mL | 0.5mg | 10 | 8–9 | Most common research vial; balances cost and 28-day stability window || 5mg | 2.5mL | 2mg/mL | 0.4mg | 12.5 | 11–12 | Preferred for lower per-dose protocols without switching vial size || 10mg | 4.0mL | 2.5mg/mL | 0.5mg | 20 | 18–19 | Requires high-frequency dosing protocols to use within 28 days || 10mg | 5.0mL | 2mg/mL | 0.33mg | 30 | 27–28 | Maximum yield; only viable for daily or near-daily administration schedules |